ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) Immutep Announces Data Presentations at Upcoming Industry Conferences SYDNEY, AUSTRALIA

ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP)

Immutep Announces Data Presentations at Upcoming Industry Conferences

SYDNEY, AUSTRALIA October 10, 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a

biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announced that clinical data on the Company s lead product candidate eftilagimod alpha ( efti or IMP321 ), a soluble

LAG-3Ig fusion protein based on the LAG-3 immune control mechanism, will be presented at two industry conferences in October and November 2019.

All presentations will be made

available on the Company s website at http://www.immutep.com/investors-media/presentations.html

Immutep is a globally active biotechnology company that is a leader in the development of immunotherapeutic products for the treatment of cancer and autoimmune

disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the

NASDAQ (IMMP) in the United States.

Immutep s current lead product candidate is eftilagimod alpha ( efti or IMP321 ), a

soluble LAG-3Ig fusion protein based on the LAG-3 immune control mechanism, is a best-and-first-in-class MHC II agonist. This mechanism plays a vital role in the regulation of the T cell immune response. Efti is currently in a Phase IIb clinical

trial as a chemoimmunotherapy for metastatic breast cancer termed AIPAC; a Phase II clinical trial being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada)

referred to as TACTI-002 (Two ACTive Immunotherapies) to evaluate a combination of efti with KEYTRUDA (or pembrolizumab, an anti-PD-1 therapy) in several different solid tumours

(clinicaltrials.gov identifier NCT03625323); a Phase I clinical trial being conducted in collaboration with Merck KGaA, Darmstadt, Germany and Pfizer Inc. referred to as INSIGHT-004 to evaluate a combination of efti with avelumab (clinical

trials.gov identifier NCT03252938); and a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel (clinicaltrials.gov identifier NCT02676869). Immutep is also developing a LAG-3 agonist monoclonal antibody for autoimmune diseases

(IMP761) that is currently in preclinical development.

Further information can be found on the Company s website www.immutep.com or by contacting:

Jay Campbell, Chief Business

Officer, Immutep Limited

+1 (917) 860-9404; jay.campbell@immutep.com

Garth Russell, LifeSci Advisors

Australian Investors/Media:

Matthew Gregorowski, Citadel-MAGNUS